XERS ▲ +0.2% - Xeris Biopharma Holdings, Inc. $XERS Barclays analyst Jenna Davidner raised the firm's price target on Xeris Biopharma to $14 from $12 and keeps an Overweight rating on the shares. The firm sees a strong setup for the company into the Q3 report with its pipeline "gaining traction." Barclays remains confident in the trajectory for Recorlev and XP-8121 and thinks Xeris' valuation "remains undemanding." 06-OCT-2026 08:22 AM ET